Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 45

Sort by

Sort Order Select

Journal Articles

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

Blood (2025) 146 (Supplement 1): 2539.

https://doi.org/10.1182/blood-2025-2539

Published: 2025

Journal Articles

Ornithine decarboxylase deficiency in donor T cells preserves strong GVL activity while attenuating acute and preventing steroid-resistant gut GVHD in a recipient tissue PD-L1-dependent manner

Qinjian Li, Boxi Lin, Yiwen Ling, Moqian Zheng, Xiwei Wu, Yuankun Zhang, James Lin, Ryotaro Nakamura, Paul Martin, Defu Zeng

Blood (2025) 146 (Supplement 1): 5868.

https://doi.org/10.1182/blood-2025-5868

Published: 2025

Journal Articles

Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells and averts lupus nephritis

Kory Hamane, Zunsong Hu, Joao Rodrigues Lima-Junior, Adeleh Taghi Khani, Anil Kumar, Ashly Sanchez Ortiz, Da Hae Jung, Hanjun Qin, Shu Tao, Ignacio Sanz, Eric Meffre, Katherine Marzan, Jean Koff, Zhaohui Gu, Xiwei Wu, Ameae Walker, Srividya Swaminathan

Blood (2025) 146 (Supplement 1): 3003.

https://doi.org/10.1182/blood-2025-3003

Published: 2025

Journal Articles

Tumor-induced dendritic cell dysfunction impairs T-cell proliferation and confers poor prognosis in high-risk acute lymphoblastic leukemia

Blood (2025) 146 (Supplement 1): 5138.

https://doi.org/10.1182/blood-2025-5138

Published: 2025

Journal Articles

DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance

Blood (2025) 146 (Supplement 1): 212.

https://doi.org/10.1182/blood-2025-212

Published: 2025

Journal Articles

Donor T-Derived Memory Progenitors Differentiated into CD103 +/- CXCR6 + CD4 + Tissue-Resident T Cell Subsets Driven Cutaneous Chronic Graft-Versus-Host Disease

Xiaohui Kong, Bixin Wang, Xiwei Wu, Weijia Fu, Qinjian Li, Moqian Zheng, Raju Pillai, Ryotaro Nakamura, Paul J. Martin, Defu Zeng

Blood (2024) 144 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2024-210519

Published: 2024

Journal Articles

Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients

Srideshikan Sargur Madabushi, Ji Eun Lim, Yu-Lin SU, Paresh Vishwasrao, Dongyun Yang, James F. Sanchez, Sally Mokhtari, Amandeep Salhotra, Xiwei Wu, Haiqing Lee, Savita Dandapani, Ryotaro Nakamura, Raju Pillai, Marcin Kortylewski, Jeffrey Wong, MHD Monzr M. Al Malki, Anthony S. Stein, Susanta Hui

Blood (2024) 144 (Supplement 1): 775.

https://doi.org/10.1182/blood-2024-211180

Published: 2024

Journal Articles

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine Zain

Blood (2024) 144 (Supplement 1): 468.

https://doi.org/10.1182/blood-2024-205617

Published: 2024

Journal Articles

Clonal Expansion and Differentiation of Stem-like Memory T Cells to Tissue-Resident Memory T Cells Perpetuates Pathogenesis of Chronic Graft-Versus-Host Disease

Xiaohui Kong, Bixin Wang, Xiwei Wu, Hyejin Cho, Moqian Zheng, Yuankun Zhang, Shanshan Tang, Qinjian Li, Ubaydah Nasri, Alyssa Wu, Hanjun Qin, Raju Pillai, Ryotaro Nakamura, Paul J. Martin, Yuanzhong Chen, Defu Zeng

Blood (2023) 142 (Supplement 1): 2044.

https://doi.org/10.1182/blood-2023-174768

Published: 2023

Journal Articles

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Christiane Querfeld, Lu Chen, Xiwei Wu, Zhen Han, ChingYu Su, Melissa Banez, Jeralyn Quach, Tiffanie Barnhizer, Liliana Crisan, Steven T. Rosen, Jasmine M. Zain

Blood (2023) 142 (Supplement 1): 3077.

https://doi.org/10.1182/blood-2023-188053

Published: 2023

Journal Articles

Acquired microRNA-142 Deficit Drives Escape Mechanisms of Anti-Leukemic Surveillance during Blast Crisis Transformation of Chronic Myeloid Leukemia (CML)

Blood (2023) 142 (Supplement 1): 3152.

https://doi.org/10.1182/blood-2023-182587

Published: 2023

Journal Articles

Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD

Xiaohui Kong, Xiwei Wu, Bixin Wang, Deye Zeng, Kaniel Cassady, Ubaydah Nasri, Moqian Zheng, Alyssa Wu, Hanjun Qin, Weimin Tsai, Amandeep Salhotra, Ryotaro Nakamura, Paul J. Martin, Defu Zeng

Blood (2022) 140 (25): 2740–2753.

https://doi.org/10.1182/blood.2022016581

Published: 2022

Includes: Supplemental data

Journal Articles

Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia

Blood (2022) 140 (Supplement 1): 998–1000.

https://doi.org/10.1182/blood-2022-165469

Published: 2022

Journal Articles

Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma

Jonathan Scott Rink, Stephen E. Henrich, Alexandra Moxley, Xu Hannah Zhang, Xiwei Wu, SonBinh Nguyen, Christiane Querfeld, David A. Horne, Steve T. Rosen, Leo I. Gordon, Colby Shad Thaxton, Adam Yuh Lin

Blood (2022) 140 (Supplement 1): 4934–4935.

https://doi.org/10.1182/blood-2022-158864

Published: 2022

Journal Articles

Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity

Blood (2022) 140 (Supplement 1): 4931–4933.

https://doi.org/10.1182/blood-2022-167366

Published: 2022

Journal Articles

Targeting Intestinal Epithelial Ceacam1 Expands Peripheral Tregs and Prevents Steroid-Refractory Acute Gut Graft-Versus-Host Disease

Qingxiao Song, Moqian Zheng, Qinjian Li, Xiwei Wu, Hanjun Qin, Tae Hyuk Kang, Yaqun Hong, Bixin Wang, Maciej Kujawski, Jack Shively, Ryotaro Nakamura, Paul J Martin, Defu Zeng

Blood (2022) 140 (Supplement 1): 10225–10226.

https://doi.org/10.1182/blood-2022-163572

Published: 2022

Journal Articles

Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma

Zhen Han, Xiwei Wu, Yate-Ching Yuan, Hanjun Qin, Chingyu Su, Jasmine Zain, Oleg E Akilov, Steve T Rosen, Mingye Feng, Christiane Querfeld

Blood (2022) 140 (Supplement 1): 6376–6377.

https://doi.org/10.1182/blood-2022-167670

Published: 2022

Journal Articles

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Farah R Abdulla, Weiwei Zhang, Xiwei Wu, Kord Honda, Hanjun Qin, Hyejin Cho, Christiane Querfeld, Jasmine Zain, Steven T. Rosen, Wing C. Chan, Vishwas Parekh, Joo Y. Song

Blood (2021) 138 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2021-152051

Published: 2021

Journal Articles

Suppressing Synthesis of the Long Isoform of the Prolactin Receptor Is a Targeted Strategy to Prevent and Treat B Cell Malignancies

Adeleh Taghi Khani, Anil Kumar, Kelly Radecki, Sung June Lee, Mary Lorenson, Xiwei Wu, Zhaohui Gu, Ameae Walker, Srividya Swaminathan

Blood (2021) 138 (Supplement 1): 1135.

https://doi.org/10.1182/blood-2021-147055

Published: 2021

Journal Articles

Tolerogenic anti–IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity

Qingxiao Song, Xiaoning Wang, Xiwei Wu, Hanjun Qin, Yingfei Li, Arthur D. Riggs, Paul J. Martin, Yuan-Zhong Chen, Defu Zeng

Blood (2021) 137 (16): 2243–2255.

https://doi.org/10.1182/blood.2020006345

Published: 2021

Includes: Supplemental data

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Targeting the METTL1/m7G axis as a therapeutic strategy in myeloid leukemia

Ornithine decarboxylase deficiency in donor T cells preserves strong GVL activity while attenuating acute and preventing steroid-resistant gut GVHD in a recipient tissue PD-L1-dependent manner

Knockdown of the long isoform of the prolactin receptor selectively targets pathogenic immune cells and averts lupus nephritis

Tumor-induced dendritic cell dysfunction impairs T-cell proliferation and confers poor prognosis in high-risk acute lymphoblastic leukemia

DDX6 undergoes phase separation to modulate metabolic plasticity and chemoresistance

Donor T-Derived Memory Progenitors Differentiated into CD103 +/- CXCR6 + CD4 + Tissue-Resident T Cell Subsets Driven Cutaneous Chronic Graft-Versus-Host Disease

Multidimensional Analysis of Relapsed Bone Marrow Reveals Cold Immune Microenvironment Post-TMLI in Acute Leukemia Transplant Patients

Randomized Phase 2 Trial of the Anti-PD-L1 Monoclonal Antibody Durvalumab Plus Lenalidomide Versus Single-Agent Durvalumab in Patients with Refractory/Advanced Cutaneous T Cell Lymphoma

Clonal Expansion and Differentiation of Stem-like Memory T Cells to Tissue-Resident Memory T Cells Perpetuates Pathogenesis of Chronic Graft-Versus-Host Disease

Preliminary Analysis Demonstrates Durvalumab (Anti-PD-L1) & Lenalidomide Is Superior to Single-Agent Durvalumab (anti-PD-L1) in Refractory/Advanced Cutaneous T Cell Lymphoma in a Randomized Phase 2 Trial

Acquired microRNA-142 Deficit Drives Escape Mechanisms of Anti-Leukemic Surveillance during Blast Crisis Transformation of Chronic Myeloid Leukemia (CML)

Trafficking between clonally related peripheral T-helper cells and tissue-resident T-helper cells in chronic GVHD

Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia

Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma

Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity

Targeting Intestinal Epithelial Ceacam1 Expands Peripheral Tregs and Prevents Steroid-Refractory Acute Gut Graft-Versus-Host Disease

Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma

Genomic Analysis of Cutaneous CD30-Positive Lymphoproliferative Disorders

Suppressing Synthesis of the Long Isoform of the Prolactin Receptor Is a Targeted Strategy to Prevent and Treat B Cell Malignancies

Tolerogenic anti–IL-2 mAb prevents graft-versus-host disease while preserving strong graft-versus-leukemia activity

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only